DrugDashboards

Wegovy

semaglutide · SEMAGLUTIDE 7.2 mg/.75mL · Injection, Solution · Subcutaneous · Novo Nordisk Pharmaceutical Industries, LP

NDC 00169-4572-14 · 4 SYRINGE, PLASTIC in 1 CARTON / .75 mL in 1 SYRINGE, PLASTIC · NDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$434.42per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$602.09per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$200.00$400.00$600.00Jun 2026Sep 2026$434.42
2 price points · per MLSource: CMS NADAC

Estimated fill cost

Estimated WAC per mLestimate
≈ $447.852
No Texas or California filing exists for this NDC — this figure is derived, not filed.

This is an ESTIMATE derived from NADAC, not a filed or published price: pharmacies typically acquire brand drugs at roughly 2–4% below list, so list ≈ NADAC ÷ 0.97. Shown only because no state transparency filing exists for this NDC.

Supply fragility

10● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for semaglutide (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,424.00 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA215256
TE code
—
Approval date
Jun 4, 2021
Patents / exclusivity
105 patents, 14 exclusivities
TypeNumber / codeExpires
exclusivityNSMar 19, 2029
exclusivityI-973Aug 15, 2028
exclusivityI-973Aug 15, 2028
exclusivityI-973Aug 15, 2028
exclusivityI-973Aug 15, 2028
exclusivityI-973Aug 15, 2028
exclusivityI-973Aug 15, 2028
exclusivityI-935Mar 8, 2027
exclusivityI-935Mar 8, 2027
exclusivityI-935Mar 8, 2027
exclusivityI-935Mar 8, 2027
exclusivityI-935Mar 8, 2027

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of semaglutide (Injection, Solution)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE 1.34 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Catalent Indiana, LLCSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Catalent Indiana, LLCSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk A/SSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 7.2 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE .68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1.34 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Pharmaceutical Industries, LPSEMAGLUTIDE 2.68 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2.27 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE .5 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 3.2 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 1 mg/mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2 mg/.5mLJul 15, 2026Sep 2, 2026
Novo Nordisk Production Belgium SASEMAGLUTIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 1.7 mg/.75mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 1 mg/.5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE .25 mg/.5mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE 2.4 mg/.75mLJul 15, 2026Sep 2, 2026
Patheon Manufacturing Services LLCSEMAGLUTIDE .5 mg/.5mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsSEMAGLUTIDE .68 mg/mLJul 31, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Wegovy — NDC 00169-4572-14," retrieved September 3, 2026, https://drugdashboards.com/drug/00169457214.

Free to cite with attribution — see how the data is put together.